scholarly journals Comparison of serum testosterone levels in prostate cancer patients receiving LHRH agonist therapy with or without the removal of the prostate

2012 ◽  
Vol 6 (3) ◽  
pp. 183-186
Author(s):  
Seetha Venkateswaran ◽  
David Margel ◽  
Stanley Yap ◽  
Karen Hersey ◽  
Paul Yip ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Serum Testosterone ◽  
Lhrh Agonist ◽  
Agonist Therapy ◽  
Testosterone Levels

Quality of life and LhRH agonist therapy among prostate cancer patients who experience PSA failure

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 9093-9093
Author(s):  
K. F. Kline ◽  
O. Sartor ◽  
N. A. Dandade ◽  
N. J. Nonzee ◽  
B. D. Vicuna ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Patients ◽  
Lhrh Agonist ◽  
Agonist Therapy ◽  
Psa Failure ◽  
Health Related Qol ◽  
Health Related ◽  
Lhrh Therapy

9093 Background: Growing numbers of prostate cancer patients survive for extended periods of time after initial diagnosis and treatment. Many experience a biochemical relapse (“PSA failure”) some time after prostatectomy or pelvic radiation. LhRH agonist therapy can reduce PSA levels, but its impact on survival time and quality of life (QOL) is unclear. We evaluated these concerns among Veterans who experienced PSA Failure. Methods: Eligibility criteria included: receipt of primary therapy for prostate cancer followed by a PSA nadir and subsequent PSA rise to at least 0.2 ng/ml. Data sources include patients (interviewer administered survey instruments on health-related QOL at baseline, 3 and 12 months) and medical records (clinical and laboratory findings). Results: 69 patients from the Jesse Brown VA Medical Center in Chicago have enrolled in the study to date. At their baseline interviews, 30 patients (43.5%) were receiving LhRH agonists (46.1% of 39 African-American patients and 48.0% of 25 White patients). LhRH agonist patients reported worse health-related QOL in domains relevant to prostate cancer than watchful waiting (WW) patients ( Table ), including increased frequency of urination, difficulty controlling urination, greater erectile dysfunction, and more limits on sexual activity. LhRH agonist and WW patients reported similar levels of sexual satisfaction. Conclusion: Of the PSA failure patients studied in this sample, those receiving LhRH agonist therapy experience more problems with urinary and sexual function than those who opted for WW. Longitudinal study will provide information about whether the LhRH therapy causes these side effects, or whether symptomatic patients are more likely to choose LhRH therapy than those with few prostate cancer symptoms. [Table: see text] No significant financial relationships to disclose.

scholarly journals Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Masayoshi Zaitsu ◽  
Mariko Yamanoi ◽  
Koji Mikami ◽  
Yuta Takeshima ◽  
Naohiko Okamoto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Metastatic Prostate Cancer ◽  
Reduction Rate ◽  
Case Series ◽  
Total Testosterone ◽  
Lhrh Agonist ◽  
Hormone Refractory Prostate Cancer ◽  
Testosterone Levels ◽  
Hormone Refractory

Background. Most patients with metastatic prostate cancer are endocrinologically treated with LHRH agonist, but finally castration-refractory and hormone-refractory cancers occur. Serum testosterone levels get low to “the castration level” by LHRH agonists but may not get low enough against castration-refractory prostate cancer.Methods. As case series, twelve patients suffering from hormone-refractory prostate cancer continuously on LHRH agonist underwent surgical castration. Additionally, one hundred and thirty-nine prostate cancer patients on LHRH agonist or surgical castration were tested for serum total testosterone levels.Results. Surgical castration caused decrease in serum PSA in one out of 12 hormone-refractory prostate cancer patients with PSA reduction rate 74%. Serum total testosterone levels were below the sensitivity threshold (0.05 ng/mL) in 40 of 89 (44.9%) medically castrated patients and 33 of 50 (66.0%) surgically castrated patients (P=.20).Conclusion. Even hormone-refractory prostate cancer patients are candidates for surgical castration because of endocrinological, oncological, and economical reasons.

PRE-TREATMENT SERUM TESTOSTERONE LEVEL IS ASSOCIATED WITH ANDROGEN RESISTANCE IN PRIMARY LHRH-AGONIST THERAPY FOR PROSTATE CANCER

2009 ◽  
Vol 181 (4S) ◽  
pp. 98-98
Author(s):  
Jeremy M Blumberg ◽  
Pejvak Sassani ◽  
T Craig Cheetham ◽  
Fang Niu ◽  
Steven J. Jacobsen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Testosterone Level ◽  
Serum Testosterone ◽  
Serum Testosterone Level ◽  
Lhrh Agonist ◽  
Agonist Therapy ◽  
Androgen Resistance ◽  
Pre Treatment

939 PROGNOSTIC ROLE OF SERUM TESTOSTERONE LEVELS IN PROSTATE CANCER PATIENTS DURING ANDROGEN-DEPRIVATION THERAPY

2012 ◽  
Vol 187 (4S) ◽  
Author(s):  
Francesco Porpiglia ◽  
Cristian Fiori ◽  
Valentina Bertaglia ◽  
Marcello Tucci ◽  
Emiliano Aroasio ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Serum Testosterone ◽  
Androgen Deprivation ◽  
Prognostic Role ◽  
Testosterone Levels

scholarly journals Discordance between testosterone measurement methods in castrated prostate cancer patients

2019 ◽  
Vol 8 (2) ◽  
pp. 132-140 ◽  
Author(s):  
Mélanie Rouleau ◽  
Francis Lemire ◽  
Michel Déry ◽  
Benoît Thériault ◽  
Gabriel Dubois ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Mass Spectrometry ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Serum Testosterone ◽  
Serum Samples ◽  
Testosterone Levels ◽  
The Mean ◽  
Low Testosterone

Failure to suppress testosterone below 0.7 nM in castrated prostate cancer patients is associated with poor clinical outcomes. Testosterone levels in castrated patients are therefore routinely measured. Although mass spectrometry is the gold standard used to measure testosterone, most hospitals use an immunoassay method. In this study, we sought to evaluate the accuracy of an immunoassay method to measure castrate testosterone levels, with mass spectrometry as the reference standard. We retrospectively evaluated a cohort of 435 serum samples retrieved from castrated prostate cancer patients from April to September 2017. No follow-up of clinical outcomes was performed. Serum testosterone levels were measured in the same sample using liquid chromatography coupled with tandem mass spectrometry and electrochemiluminescent immunoassay methods. The mean testosterone levels were significantly higher with immunoassay than with mass spectrometry (0.672 ± 0.359 vs 0.461 ± 0.541 nM; P < 0.0001). Half of the samples with testosterone ≥0.7 nM assessed by immunoassay were measured <0.7 nM using mass spectrometry. However, we observed that only 2.95% of the samples with testosterone <0.7 nM measured by immunoassay were quantified ≥0.7 nM using mass spectrometry. The percentage of serum samples experiencing testosterone breakthrough at >0.7 nM was significantly higher with immunoassay (22.1%) than with mass spectrometry (13.1%; P < 0.0001). Quantitative measurement of serum testosterone levels >0.7 nM by immunoassay can result in an inaccurately identified castration status. Suboptimal testosterone levels in castrated patients should be confirmed by either mass spectrometry or an immunoassay method validated at low testosterone levels and interpreted with caution before any changes are made to treatment management.

Maintenance of the suppressed level of serum testosterone by administration of three-monthly formulations of luteinizing hormone-releasing hormone agonists at six-month intervals in Japanese patients with prostate cancer: A prospective study.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 159-159
Author(s):  
Y. Fujii ◽  
S. Yoshida ◽  
M. Yokoyama ◽  
Y. Iimura ◽  
N. Numao ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Serum Testosterone ◽  
Japanese Patients ◽  
Serum Testosterone Level ◽  
Testosterone Levels ◽  
Serum Lh ◽  
One Year ◽  
Lh Rh ◽  
Prospective Longitudinal

159 Background: Treatment with an LH-RH agonist is a standard alternative to surgical castration for prostate cancer patients. The serum testosterone level is kept at castrate levels continuously during LH-RH agonist therapy in almost all patients (Fujii Y, BJU Int 2008). LH- RH agonists, however, are more expensive than surgical castration, with drugs costing between US $300 and $500 per month in Japan. Recent studies suggest that 3-monthly formulations of LH-RH agonists suppress the serum testosterone levels far longer than the 3-month dosing interval. Methods: A total of 43 Japanese patients with prostate cancer who were treated with 3-monthly LH-RH agonists (23 with 11.25mg leuprolide, and 20 with 10.8 mg goserelin) for one year or longer and whose testosterone levels were kept at castrate level (defined as < 50 ng/dL) were entered into this prospective, longitudinal study. After entry, the 43 men received the same 3-monthly LH-RH agonists at 6-month intervals, and had serum LH and testosterone tests performed at 3-month intervals. Bicalutamide was combined with the LH-RH agonists in 12 of the patients. Results: At entry, median patient age was 74 years (range 59 to 89), median duration of LH-RH agonists treatment was 26 months (12 to 125), and median LH and testosterone levels were <10 ng/dL (<10 to 60) and 5 ng/dL (<5 to 18), respectively. The 43 patients received a total of 162 administrations (median 5, range 1 to 6) of the LH-RH agonists at 6-month intervals, and had a total 335 hormonal tests (median 10, range 2 to12) performed during the median followup period of 30 months. Serum LH and testosterone levels were kept suppressed during the treatment. Of the 43 patients, two had serum testosterone just above the castrate level (54 and 56 ng/dL) once each among their 12 and 8 hormonal assays, respectively. Conclusions: Administration of 3-monthly LH-RH agonists, either leuprolide or goserelin, at 6-month intervals could maintain the castrate level of serum testosterone at least in Japanese prostate cancer patients who have received LH-RH agonists treatment for one year or longer. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document